AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 38.12 |
Market Cap | 3.70B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -6.35 |
PE Ratio (ttm) | -6.32 |
Forward PE | n/a |
Analyst | Buy |
Ask | 46.12 |
Volume | 788,455 |
Avg. Volume (20D) | 842,022 |
Open | 44.52 |
Previous Close | 43.16 |
Day's Range | 39.79 - 44.52 |
52-Week Range | 37.02 - 60.37 |
Beta | undefined |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia...
Analyst Forecast
According to 14 analyst ratings, the average rating for RARE stock is "Buy." The 12-month stock price forecast is $84.5, which is an increase of 110.67% from the latest price.
Next Earnings Release
Analysts project revenue of $144.99M, reflecting a 13.81% YoY growth and earnings per share of -1.35, making a -11.18% decrease YoY.
2 months ago · seekingalpha.com
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call TranscriptUltragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO H...